Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
API
0
FDF
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 17-(cyclopropylmethyl)-6,7-didehydro-4,5alpha-epoxy-3,6,14-trihydroxy-n-(2-(3-phenyl- 1,2,4-oxadiazol-5-yl)propan-2-yl)morphinan-7-carboxamide
2. Naldemedine
3. S-297995
4. Symproic
1. Symproic
2. Naldemedine Tosilate
3. Naldemedine Tosylate [usan]
4. Naldemedine (tosylate)
5. V1n8f1rvvo
6. 1345728-04-2
7. Unii-v1n8f1rvvo
8. Symproic (tn)
9. Chembl3039508
10. Schembl20720003
11. Dtxsid10158809
12. Naldemedine Tosylate [mi]
13. Naldemedine Tosylate (jan/usan)
14. Naldemedine Tosilate [jan]
15. Hy-19627a
16. Naldemedine Tosilate [who-dd]
17. Naldemedine Tosylate [orange Book]
18. Cs-0030916
19. D10478
20. Q27291424
21. 17-(cyclopropylmethyl)-6,7-didehydro-4,5a-epoxy-3,6,14-trihydroxy-n-(2-(3-phenyl-1,2,4-oxadiazol-5-yl)propan-2-yl)morphinan-7-carboxamide 4-methylbenzenesulfonic Acid
22. Morphinan-7-carboxamide, 17-(cyclopropylmethyl)-6,7-didehydro-4,5-epoxy-3,6,14-trihydroxy-n-(1-methyl-1-(3-phenyl-1,2,4-oxadiazol-5-yl)ethyl)-,(5.alpha.)-, 4-methylbenzenesulfonate (1:1)
23. Morphinan-7-carboxamide, 17-(cyclopropylmethyl)-6,7-didehydro-4,5-epoxy-3,6,14-trihydroxy-n-(1-methyl-1-(3-phenyl-1,2,4-oxadiazol-5-yl)ethyl)-,(5alpha)-, 4-methylbenzenesulfonate (1:1)
Molecular Weight | 742.8 g/mol |
---|---|
Molecular Formula | C39H42N4O9S |
Hydrogen Bond Donor Count | 5 |
Hydrogen Bond Acceptor Count | 12 |
Rotatable Bond Count | 7 |
Exact Mass | 742.26725010 g/mol |
Monoisotopic Mass | 742.26725010 g/mol |
Topological Polar Surface Area | 204 Ų |
Heavy Atom Count | 53 |
Formal Charge | 0 |
Complexity | 1340 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 4 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 1 | |
---|---|
Drug Name | SYMPROIC |
Active Ingredient | NALDEMEDINE TOSYLATE |
Company | SHIONOGI INC (Application Number: N208854. Patents: 9108975, RE46365, RE46375) |
Rizmoic is indicated for the treatment of opioid-induced constipation (OIC) in adult patients who have previously been treated with a laxative.
Treatment of opioid-induced constipation (OIC)
A06AH05
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?